Siemens Healthineers: A Stock at 35.75 Euros Faces a Crucial Test on May 7

Siemens Healthineers shares hit oversold territory near 52-week low, but analysts expect solid Q2 earnings and AI-driven growth, with a looming 13.9B euro debt spin-off risk.

The numbers tell a stark story. Siemens Healthineers shares closed at 35.75 euros on Friday, having shed nearly a fifth of their value since January. The relative strength index sits at 25.5 — deep in oversold territory — and the gap to the 200-day moving average has stretched to roughly 18 percent. At one point during the session, the stock brushed against its 52-week low of 35.66 euros.

Yet the company’s operational outlook paints a very different picture. Analysts expect second-quarter earnings per share of 0.51 euros when the books open on May 7, with revenue stabilizing near six billion euros. For the full year, the consensus sits at around 2.30 euros per share, while management’s own guidance targets 2.20 to 2.40 euros — a range that brackets last year’s 2.39 euros despite headwinds that include roughly 400 million euros in tariff costs and up to 250 million euros in negative currency effects.

The disconnect between price and fundamentals is the central puzzle for investors. And it is about to get a reality check.

A Basel Showcase With a Purpose

This week, the company is in Basel for the European Conference on Interventional Oncology, where it is rolling out its revamped ARTIS angiography portfolio. The new platforms — Artis genio, Artis icono.explore, and Artis icono.vision — lean heavily on artificial intelligence to improve embolization treatments for liver cancer. Features include automated motion correction in 3D datasets and a new imaging chain that delivers higher quality without increasing radiation dose.

The accompanying myEmbolization Guide, an organ-specific algorithm trained for liver, prostate, or general workflows, automates manual tasks and supports decision-making during procedures. Interventional oncology is positioned internally as a growth driver for the advanced therapies division.

These innovations are part of a broader strategic push into higher-margin segments. The company recently secured a supply agreement for a radiologically labeled agent in brain metastasis research and is backing the ScreenPoint Medical AI platform for breast cancer diagnostics.

The 14 Billion Euro Question

But product launches and AI partnerships cannot mask the structural issue looming over the stock. The planned spin-off by Siemens AG — to be voted on at the parent company’s annual general meeting in February 2027 — will leave Siemens Healthineers without the parental guarantee on loans totaling up to 13.9 billion euros.

That debt load will need to be refinanced independently. For a company that reported adjusted earnings per share of just 0.49 euros in the first quarter — down 3 percent year-on-year — the capital structure implications are significant. First-quarter revenue grew 3.8 percent, but the diagnostics division took a 3 percent hit from China’s anti-corruption campaign, a drag that investors will watch closely in the May 7 report.

What the Charts Say

Technically, the stock is oversold to a degree that historically has preceded rebounds. The RSI at 25.5 signals a downward exaggeration, and the distance to the 200-day moving average suggests mean reversion potential. But the trend remains firmly negative, and a weak second-quarter report could open the door to a test below 35 euros.

The average analyst target of 53 euros implies substantial upside from current levels. Whether that optimism is justified depends on whether management can convince the market that the China diagnostics headwind is stabilizing and that the spin-off’s refinancing challenge is manageable.

The May 7 earnings release will provide the first hard data point. If the numbers confirm operational stability, the selling pressure loses its fundamental anchor. If they disappoint, the next support level sits uncomfortably close.